tients with this disease (2) (3) (4) (5) . Furthermore, attempts at treatment are often frustrated by P. aeruginosa's predilection to develop resistance to conventional antibiotics (6) .
An impressive amount is known about host conditions that predispose patients to developing nosocomial pneumonia caused by P. aeruginosa or other bacterial pathogens. Several studies have demonstrated that previous antibiotic use is associated with an increased risk of nosocomial pneumonia (2, 5, 7) . Antibiotic usage alters bacterial flora in the upper respiratory tract, allowing resistant nosocomial pathogens to colonize patients (8) and subsequently cause pneumonia. Duration of mechanical ventilation, length of stay in the hospital, increased age, and severity of underlying illness also predispose to these infections (5, 7) . Once pneumonia has developed, additional host factors predict which patients will experience more severe disease. Immunosuppression (9) , prolonged duration of ventilation, coma on admission, renal insufficiency (10) , age Ͼ60 yrs, an ultimately terminal underlying condition (11) , shock, and multiple system organ failure (12) are all important risk factors for severe disease in these patients. Acute
Physiology and Chronic Health Evaluation II score at the time of diagnosis but not at admission correlates with a worse outcome (3, 4) , as does treatment with an inadequate antibiotic regimen (9, 13, 14) . Although increasing multidrug resistance continues to complicate therapy, the pathogenicity of P. aeruginosa appears to be related primarily to its toxin repertoire.
Through the use of animal models, a number of P. aeruginosa factors that contribute to lung injury in pneumonia have also been identified. Exotoxin A is a secreted adenosine diphosphate (ADP)-ribosyltransferase that injures cells by modifying the structure of elongation factor-2, which results in decreased translation (15, 16) . Although one study showed that exotoxin A did not play a role in acute lung injury (17) , others have observed decreased pathology in animal models of chronic pneumonia infected with exotoxin A-deficient mutants (18) . Furthermore, intratracheally instilled exotoxin A causes pulmonary histopathology similar to that seen in experimental infections (19) . P. aeruginosa cultures are also associated with enzymatic activity that degrades elastin, a common protein in the lung and blood vessel walls. This enzymatic activity was originally ascribed to a bacterial product named elastase but is now known to result from the activities of two proteins: LasA and LasB (reviewed in 20) . Although studies using a rabbit model suggested that elastase does not play a role in the pathogenesis of acute pneumonia (21) , P. aeruginosa mutants deficient in production of elastase activity were associated with decreased mortality in guinea pig, mink, and neonatal mouse models of acute pneumonia (17, 22, 23) and with less pathology in a rat model of chronic pneumonia (18) . In addition, P. aeruginosa strains isolated from lungs secreted more elastase than strains isolated from other sites of infection (24), and intranasally instilled elastase caused pulmonary toxicity in mice (25) and in rats (19) . Phospholipase C, a lecithinase postulated to play a role in lung infections because of the importance of lecithin in normal lung function, contributed to lung injury and bacterial persistence in rabbit and rat models of pneumonia (21, 26) . Additional secreted products, such as siderophores and proteases, may also be important in the pathogenesis of P. aeruginosa pulmonary infections (25, 27 ).
An important and recently recognized virulence system of P. aeruginosa is the type III secretion system (reviewed in 28). This system uses complex secretion/ translocation machinery to inject a set of factors, called effector proteins, directly into the cytoplasm of eukaryotic cells. The genes that encode the proteins involved in secretion and translocation are clustered together in a 25-kb locus on the P. aeruginosa chromosome. At least portions of this large locus are present in all P. aeruginosa isolates examined to date (29). Examples of genes in this cluster are psc genes, which primarily encode components of the type III secretion apparatus embedded in the bacterial cell envelope, the pcr and exs genes, the products of which regulate expression and secretion, and the popB and popD genes, which encode proteins essential for translocation of effector proteins into the host cell cytoplasm (reviewed in 28). Studies using animals suggested that this complex system is important in disease. For example, mutants defective in production of type III secretion regulatory factors or components of the secretion apparatus were less virulent than isogenic wild-type strains in rabbit, rat, or mouse models of acute pneumonia (21, 30, 31; A.R. Hauser and J.N. Engel, unpublished data). Thus, the P. aeruginosa type III secretion system is an attractive candidate for an important virulence determinant in hospital-acquired pneumonia.
Four effector proteins, which are secreted and translocated by the type III system, have been identified in P. aeruginosa: ExoS, ExoT, ExoU (also called PepA), and ExoY. The genes that encode these proteins are not clustered but scattered throughout the P. aeruginosa chromosome (32). The exoT and exoY genes are present in nearly all clinical isolates, but a significant number of isolates lack either the exoS or the exoU gene (29, 33, 34). Recent work has significantly improved our understanding of the proteins encoded by these genes. ExoS possesses two distinct functional domains. The amino-terminus has GTPase-activating activity for Rho GTPases and causes disruption of actin, which results in cell rounding (35-38). The carboxyl-terminus exhibits ADP-ribosyltransferase activity directed toward Ras and other proteins and is cytotoxic to eukaryotic cells (35, 39 -42) . In addition, ExoS may play a role in modulating bacterial internalization by eukaryotic cells (35, 43, 44) . The effector protein ExoT, also a GTPaseactivating protein for Rho GTPases, inhibits bacterial internalization by eukaryotic cells (43, 45, 46) and contributes to virulence in a mouse model of pneumonia (45) . ExoY is an adenylate cyclase that elevates the intracellular cAMP levels in eukaryotic cells and causes rounding of certain cell types (38, 47) . Although the mechanism of action of the fourth effector protein, ExoU, is unclear, laboratory studies suggest that it is of particular importance in disease. ExoU mediates killing of a variety of mammalian cell types in vitro, including macrophages, epithelial cells, and fibroblasts (33, 34, 38, 44, 48, 49) . Furthermore, isogenic mutants that do not produce or secrete ExoU are less virulent in a mouse model of pneumonia (33, 34), and an exoU-exoT double-mutant is defective in causing sepsis in a rabbit model of pneumonia (50) . Introduction of the exoU gene into several strains that do not naturally harbor it resulted in increased virulence of these strains in a mouse model of acute pneumonia (51) .
In contrast to the significant literature on the effects of P. aeruginosa factors in tissue culture and animal models of pneumonia, little is known about the role of these factors in human disease. In particular, it remains unclear whether secretion of certain virulence determinants allows some clinical isolates of P. aeruginosa to cause more severe infections in humans. This study examined whether clinical isolates of P. aeruginosa obtained from patients with ventilatorassociated pneumonia (VAP) harbored type III secretion genes and were capable of secreting type III proteins. In addition, type III secretion characteristics were compared with patient outcomes. Our hypothesis was that the production of type III secretory proteins was associated with poor outcomes.
MATERIALS AND METHODS
Bacterial Isolates. All P. aeruginosa strains were grown from frozen cultures originally isolated from patients with VAP at Sabadell Hospital, Barcelona, Spain, between May 1993 and October 1997. Some of these episodes have been previously reported as parts of studies with other objectives (3, 52) . No patients had cystic fibrosis or neutropenia. The diagnosis of VAP was considered when new and persistent pulmonary infiltrates that were not otherwise explained appeared on chest roentgenograms. In addition, at least two of the following criteria were required: temperature of Ն38°C, leukocytosis Ն10,000 cells/mm 3 , and purulent respiratory secretions. Pneumonia was deemed ventilator-associated if its onset occurred after 48 hrs of mechanical ventilation and it was judged not to have developed before the start of mechanical ventilation (53) . Fiberoptic bronchoscopy with a protected specimen brush or bronchoalveolar lavage was performed within 12 hrs of the development of new pulmonary infiltrates. The diagnosis of P. aeruginosa pneumonia was confirmed if the protected specimen brush yielded Ն1,000 colony-forming units (cfu)/mL of P. aeruginosa or bronchoalveolar lavage fluid yielded Ն10,000 cfu/mL of P. aeruginosa. The study was approved by the Institutional Review Board. Thus, informed consent was obtained from the patients or their parents or guardians, and guidelines for human experimentation at the authors' institutions were followed in the conduct of the clinical research. P. aeruginosa strain PA103, which produces ExoU but not ExoS (33, 34), and strain 388, which produces ExoS but not ExoU (data not shown and 54), were used as controls in Southern hybridization and immunoblot experiments. After thawing from frozen cultures, bacterial isolates were grown on VogelBonner minimal media agar plates (55) without repassaging. Before purification of chromosomal DNA, bacteria were grown at 37°C for approximately 17 hrs in Luria Bertani broth with vigorous shaking. For analysis of type-III-secreted proteins, P. aeruginosa strains were grown in MINS medium (54, 56) for approximately 17 hrs at 37°C with vigorous shaking.
Construction of Labeled Gene-Specific Probes. An exoU-hybridizing probe was generated and labeled using the polymerase chain reaction (PCR) with upstream (5'-AGCGT-TAGTGACGTGCG-3') and downstream (5'-GCGCTCGCTCTTCAACGG-3') primers in the presence of digoxigenin-11-dUTP (Roche Molecular Biochemicals, Indianapolis, IN) to amplify a 1.1-kb internal fragment of the exoU gene. An exoS-hybridizing probe was generated and labeled using upstream (5'-TTTG-GATCCATGCATATTCAATCGCTTCAGCAGA-3') and downstream (5'-CCCCTTAAGTCAGGC-CAGGTCGAGGCCGCG-3') primers to amplify a 1.4-kb probe. A popB-specific probe was generated and labeled in the same manner using upstream (5'-TTTGGATCCATGAATCCGATA-ACGCTTG-3') and downstream (5'-TTTGAAT-TCTCAGATCGCTGCCGGTCG-3') primers to generate a 1.2-kb internal fragment of the popB gene. Cloned or chromosomal copies of each gene were used as templates. In each case, the following protocol was used to amplify the desired DNA products: 94°C ϫ 30 secs, 50°C ϫ 30 secs, 72°C ϫ 2 mins, 40 total cycles, final extension at 72°C ϫ 5 mins. Amplified and labeled DNA fragments were electrophoresed through agarose gels (0.8%) and the appropriately sized DNA fragments extracted and used as probes in Southern hybridization experiments.
Southern Hybridization Analysis. Southern hybridizations were performed using the DIG System (Roche Molecular Biochemicals) in accordance with the manufacturer's instructions. Chromosomal DNA from clinical isolates was purified by the method of Chen and Kuo (57) . DNA was digested with BamHI, electrophoresed through agarose gels (0.8%), and transferred to nylon membranes (Hybond-N, Amersham, Arlington Heights, IL). Prehybridization incubations were performed in 5 ϫ SSC (SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 0.02% SDS, 0.1% N-lauroyl-sarcosine, and 1% Blocking Reagent (Roche Molecular Biochemicals) at 68°C for 2 hrs. Hybridization incubations were performed under identical conditions except that labeled probe was added and the incubation time was lengthened to 17 hrs. Membranes were washed twice in 2 ϫ SSC, 0.1% SDS for 15 mins at room temperature followed by two washes in 0.5 ϫ SSC, 0.1% SDS for 15 mins at 68°C. Membranes were then rinsed in washing buffer (0.3% [w/v] Tween 20 in 0.1 M maleic acid, 0.15 M NaCl, pH 7.5) and incubated in blocking buffer (1% Blocking Reagent in 0.1 M maleic acid, 0.15 M NaCl, pH 7.5) for 1 hr at room temperature. Membranes were next incubated for 30 mins at room temperature in anti-DIG-POD Fab fragments (Roche Molecular Biochemicals) diluted 1:1000 in blocking buffer. Membranes were then washed twice in washing buffer for 15 mins at room temperature. Labeled DNA fragments were visualized by incubating the membranes in 225 M coumaric acid (Sigma Chemical, St. Louis, MO), 1.25 mM 3-aminophthalhydrazide (Sigma Chemical), and 0.009% hydrogen peroxide (Fisher Scientific, Pittsburgh, PA) in 100 mM Tris pH 8.5 for 1 min and then exposing the membranes to autoradiography film. Each membrane was subsequently re-exposed to additional type III secretion probes to ensure that sufficient DNA was present in each lane for gene detection.
Immunoblot Analysis. Supernatants were obtained from 5-mL cultures by centrifugation at 6000 ϫ g at 4°C for 20 mins. Proteins present in supernatants were precipitated by the addition of ammonium sulfate (55% final concentration). After incubation on ice for 2 hrs, the precipitated material was isolated by centrifugation at 13,000 ϫ g at 4°C for 20 mins. The pellet was boiled in 500 L of 1 ϫ SDS-PAGE sample buffer (58) for 5 mins, and 75 L of each sample was electrophoresed through an 8% SDS-polyacrylamide gel. For immunoblot analysis, proteins were electrotransferred from SDSpolyacrylamide gels to nitrocellulose (Schleicher and Schuell, Keene, NH) and hybridized with a mixture of antiserum against ExoU, ExoT, PopB, and PopD (59) . Because of the similarity between ExoT and ExoS (75% amino acid identity), the ExoT antisera also recognized ExoS. Polyclonal rabbit antisera against these proteins were prepared as described previously (34). Goat anti-rabbit IgG horseradish peroxidase conjugate (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:5000 was used as a secondary antibody. Detection was performed using autoradiography after incubation with coumaric acid and 3-aminophthalhydrazide as described in the section on Southern hybridizations.
Clinical Outcomes. Clinical resolution was defined as complete abatement of all signs and symptoms of pneumonia along with resolution or lack of progression of all abnormalities on the chest radiograph (60) . Deaths were considered related to the pulmonary infection if patients died before any objective response to antimicrobial therapy or if the pulmonary infection was thought to be a contributing factor to death in cases with other co-morbidities (5). Deaths resulting from other causes were defined as those deaths that occurred after resolution of pneumonia. Recurrent pneumonia caused by P. aeruginosa was defined as follows: 1) occurrence at least 72 hrs after clinical resolution of the initial episode of pneumonia; 2) positive bronchoscopic quantitative culture for P. aeruginosa; 3) evidence of a new infiltrate on chest radiograph; 4) two of the following: a) fever Ն38°C, b) peripheral white blood cell count Ն10,000/mm 3 , or c) purulent respiratory secretions; and 5) absence of evidence of a new extrapulmonary source of infection (52) . All patients received early and appropriate antibiotic therapy, as defined by the use of two or more agents to which the P. aeruginosa isolate was susceptible starting at the time the diagnostic test was performed. Antibiotic therapy was continued for at least 2 wks after the bronchoscopic procedure.
Statistical Analysis. Categorical variables were compared using the chi-square test or Fisher's exact test when appropriate.
RESULTS
Thirty-five P. aeruginosa VAP isolates from our collection were selected for use in this study. Each isolate had been collected using protected brush sampling or bronchoalveolar lavage from patients who met strict criteria for VAP (53) . Pulse-field gel electrophoresis of restriction endonuclease digested chromosomal DNA demonstrated that the isolates were predominantly nonclonal (52, data not shown) and therefore did not represent multiple isolates from one or several epidemics. Isolates were selected to represent a range of clinical outcomes (Table  1 ). Nineteen isolates were from patients who died after their episode of VAP. In ten of these patients, death was judged to be related to the pneumonia. Nine isolates were cultured from patients who uneventfully recovered from VAP after administration of appropriate antibiotic therapy. Six isolates were cultured from patients who experienced relapses of VAP despite appropriate antibiotic treatment. Each relapse was shown to be the result of the original infecting isolate by pulsefield gel electrophoresis (52) .
All isolates were analyzed in a blinded fashion for the presence of a type III secretion system. The popB gene, which encodes a component of the translocation complex, was used as a marker for the presence of a 25-kb cluster of type III secretion genes located in the P. aeruginosa chromosome. Southern hybridization experiments indicated that in each isolate a single BamHI-BamHI fragment of DNA hybridized to the popB probe (Fig. 1B, data not shown) . Thus, at least a portion of the P. aeruginosa type III secretion system was present in all examined isolates. Immunoblot analyses were next performed to determine whether these secretion systems were functional in vitro. Isolates were grown in calciumdepleted medium, conditions known to induce P. aeruginosa type III secretion in vitro (61, 62) . Culture supernatants were collected, concentrated, and partially purified using ammonium sulfate precipitation. To detect type-III-secreted proteins, immunoblot analyses were performed using antisera that recognize ExoU, ExoS, ExoT, PopB, and PopD (Fig. 2, data not  shown) . Twenty-seven (77%) of the 35 examined isolates secreted at least one of these type III proteins whereas 8 isolates (23%) did not secrete detectable amounts of any of these type III secretion proteins under these growth conditions (Table 1) .
Because functional type III secretion has been associated with increased virulence in animal models of pneumonia (21, 30 , 31), we examined whether the clinical outcomes of patients infected with type-III-secreting isolates were worse than those of patients infected with nonsecreting isolates. Of note, at the time of diagnosis each patient had begun an appropriate regimen of antibiotics, defined as two or more agents to which the P. aeruginosa isolate was susceptible in vitro. Thus, differences in clinical outcomes were not the result of inadequate antibiotic therapy. Patients were categorized as having severe disease if they died or suffered a relapse of VAP caused by the same isolate. Patients who uneventfully recovered from their episode of VAP were categorized as having mild disease. Of the 27 patients infected with type-III-secreting isolates, 22 (81%) had severe disease.
In contrast, of the eight isolates that did not secrete type III proteins, only three (38%) were cultured from patients with severe disease, a statistically significant difference (p Ͻ .05). This difference in outcome remained statistically significant when severe disease was redefined as patients who relapsed or suffered related (as opposed to crude) mortality (56% severe disease in type-III-secreting isolates vs. 13% severe disease in isolates that did not type III secrete, p Ͻ .05). These findings suggest that P. aeruginosa isolates capable of secreting detectable amounts of type III proteins in vitro are associated with more severe disease in patients with VAP.
We next wished to determine whether ExoU secretion by a subset of the type-III-secreting isolates was responsible for the type-III-secreting isolates as a group being associated with more severe disease. This is an attractive hypothesis because ExoU is an important determinant of mortality in animal models of P. aeruginosa acute pneumonia (33, 34, 50).
All isolates were analyzed for ExoU production. Southern hybridization analysis indicated that 12 (34%) of the 35 examined isolates harbored the exoU gene (Fig. 1A, data not shown) . No isolate contained more than one DNA fragment that hybridized to the exoU-specific probe. To determine whether isolates harboring the exoU gene were capable of secreting ExoU, immunoblot analyses were performed on supernatants of cultures grown under conditions that induce type III secretion (Fig. 2, data not shown) . With two exceptions (PSE1 and PSE7), all 12 of the isolates that contained the exoU gene secreted detectable amounts of ExoU in vitro (Table 1) .
Clinical outcomes in patients infected with ExoU-secreting isolates of P. aeruginosa were compared with those of patients infected with isolates that did not secrete type III proteins (ExoU, ExoS, ExoT, PopB, or PopD). Of the patients infected with the ten ExoU-secreting isolates, nine (90%) had severe disease, compared with three (38%) of eight non- Death, crude Totals  27  12  10  23  16 secreting isolates, a statistically significant difference (p Ͻ .05). A trend toward more severe disease in patients infected with ExoU-secreting isolates remained when severe disease was redefined as relapse or related mortality, but this association did not reach statistical significance (50% vs. 13%, p ϭ .22). Thus, infection with ExoU-secreting isolates was associated with worse clinical outcomes than infection with isolates that did not secrete type III proteins.
Isolates were also examined for the production of ExoS using Southern hybridization and immunoblot analyses. The exoS gene was present in 23 (66%) of the 35 examined isolates (Fig. 1C , Table  1 , data not shown). In agreement with previous reports (29), every isolate that contained the exoS gene did not contain the exoU gene and vice versa (Table 1) . Sixteen (70%) of these 23 isolates secreted detectable amounts of ExoS in vitro (Fig. 2, data not shown) . Twelve (75%) of these 16 isolates were cultured from patients with severe disease compared with 3 (38%) of 8 nonsecreting isolates (p ϭ .14). A trend toward more severe disease in patients infected with ExoS-secreting isolates remained when severe disease was redefined as related mortality or relapse (56% vs. 38%, p ϭ .11). These results suggest that ExoSproducing isolates may be associated with more severe disease than isolates that do not secrete type III proteins, although larger studies are necessary to fully define the role of ExoS in human disease. No significant difference in disease severity was noted when ExoU-secreting isolates were compared with ExoS-secreting isolates (90% vs. 75%, p ϭ .34).
DISCUSSION
Our results show that secretion of type III proteins by lower respiratory tract isolates from intubated patients with P. aeruginosa pneumonia is associated with more severe disease. It is important to note that P. aeruginosa is adept at colonizing the upper airways of mechanically ventilated patients and is often present in tracheal aspirates or unprotected bronchoscopic samples from patients without pneumonia. Therefore, we limited our study to isolates obtained by quantitative bronchoscopy of patients who met accepted criteria for the diagnosis of VAP (53) . Using only these clinically wellcharacterized isolates, we were able to show that type III secretion appears to be important in the disease process of VAP, one of the most serious P. aeruginosa infections.
Given that type-III-secreting isolates caused more severe disease in patients Figure 1 . Representative Southern hybridization results of 10 Pseudomonas aeruginosa isolates from patients with VAP. A, BamHI-digested chromosomal DNA hybridized with labeled exoU-specific probe. PSE 1, PSE 4, PSE 7, and PSE 10 each contain DNA fragments that hybridize to the exoU probe. PA103 is a control strain that contains the exoU gene but not the exoS gene (33, 34, data not shown). 388 is a control strain that lacks the exoU gene but contains the exoS gene (47, 68) . B, the same membrane as in panel A, but hybridized with both exoU-and popB-specific probes. The popB-specific probe hybridizes to DNA fragments in each lane, confirming that each sample contains at least a portion of the large chromosomal cluster of type III secretion genes and that sufficient amounts of DNA are present for detection of individual genes. C, digested chromosomal DNA from the same isolates hybridized with labeled exoS-specific probe. PSE2, PSE3, PSE5, PSE6, PSE8, and PSE9 each contain DNA fragments that hybridize to the exoS probe. Figure 1 . Culture supernatants were electrophoresed through SDS-polyacrylamide gels and transferred to membranes that were subsequently exposed to a mixture of antisera that recognize ExoS, ExoT, ExoU, PopB, and PopD. Some isolates, such as PSE1, do not secrete detectable amounts of any of these type-IIIsecreted proteins under these growth conditions. Other isolates, such as PSE 4 and PSE 10, secrete ExoU and other type-III-secreted proteins while still other isolates, such as PSE2, PSE3, PSE5, PSE6, PSE8, and PSE9, secrete ExoS and other type-III-secreted proteins. Note that ExoT secreted by some isolates, such as PSE4 and PSE10, migrates faster on SDS-protein gels than does ExoT secreted by other isolates. PA103 is a control strain that secretes ExoU, ExoT, PopB, and PopD.
with VAP, we next wished to investigate whether ExoU was responsible for this increased virulence. Several observations made in laboratory studies suggested that this might be the case. Mutant strains of P. aeruginosa that do not secrete ExoU cause decreased amounts of cell death in tissue culture systems and attenuated disease in animal models of acute pneumonia (33, 34, 50). In this regard, we found that ExoU-secreting isolates more frequently caused severe disease than did isolates that did not type-III-secrete. However, ExoS-secreting isolates were also associated with more severe disease than nonsecreting isolates, although the association was not statistically significant. The inverse relation between ExoU and ExoS secretion among isolates makes it difficult to draw firm conclusions from these results. One possibility is that both ExoU and ExoS are potent toxins in humans and that ExoS may compensate for the absence of ExoU in severe infections caused by type-III-secreting strains. Alternatively, it is conceivable that ExoU and ExoS play only minor roles in human disease and that a second type-IIIsecreted factor, such as ExoT, is responsible for the poor clinical outcomes associated with secreting isolates. ExoT does contribute to virulence in a mouse model of acute pneumonia, although its effect is subtler than that of ExoU (45) . Unlike ExoU and ExoS, ExoT was secreted by nearly all the type-III-secreting isolates in our study (data not shown) and therefore was also associated with severe disease. Finally, multiple type-III-secreted factors acting in concert may be responsible for poor clinical outcomes in patients with VAP. Each of the known type III effector proteins (and perhaps yet-to-be-identified effector proteins) may contribute to the overall level of disease severity. In this case, the total absence of type III secretion would be associated with a dramatic decrease in virulence, whereas the absence of a single effector protein, such as ExoU, would result in only minor changes in disease severity. Larger studies are necessary to better define the relative contributions of ExoU, ExoS, and other type-III-secreted proteins to virulence.
It is of interest that a significant fraction of VAP isolates do not secrete type III proteins. The reason for this is unclear but does not appear to be a result of the total absence of type-III-secretion genes. In agreement with previous reports (29), we found that all examined isolates harbored at least a portion of the large chromosomal cluster of genes encoding type III secretion machinery and regulatory proteins. However, only about threequarters of these isolates were capable of secreting type III proteins in vitro. Another possible explanation is that the nonsecreting isolates harbored defective alleles of the exsA gene, which encodes the transcriptional activator of the type III system (62, 63) . Dacheux and colleagues (64) have demonstrated that type III secretion by some P. aeruginosa isolates cultured from patients with cystic fibrosis is restored when these isolates are complemented with a functional exsA allele. However, other explanations, such as mutations in genes encoding structural components of the type III pathway, are also plausible. Alternatively, isolates categorized as nonsecreting may actually secrete very low levels of type III proteins that are undetectable by our immunoblot assays. This would not significantly alter our conclusions but would indicate that disease severity correlates with the level of type III secretion. In either case, our findings suggest that P. aeruginosa isolates causing VAP can be divided into two phenotypic groups: those that secrete detectable amounts of type III proteins and those that do not. Furthermore, the ability to secrete detectable amounts of type III proteins (at least in vitro) is not required for P. aeruginosa to cause VAP.
That type III secretion contributes to disease severity in VAP has several important implications with regard to P. aeruginosa pathogenesis. First, the numerous studies examining the effects of type III proteins in animal models of pneumonia (21, 30, 31, 33, 34, 50, 51, 65) are relevant to human disease. Also, in the context of the many known and putative virulence determinants of P. aeruginosa (reviewed in 66), type III secretion systems are likely to be especially important in disease in that secretion of these proteins identifies particularly virulent strains. The mechanism by which type-III-secreted proteins cause severe disease is unclear but may involve prevention of an adequate host immune response or predisposition to septic shock (50) . In any case, neutralization of secreted and nonsecreted components of the type III system through active or passive immunization may prove an efficacious therapeutic intervention in patients with VAP, as suggested by animal studies (65) .
The finding that type-III-secreting isolates of P. aeruginosa are associated with poor outcomes in patients with VAP is not only of academic interest but also has several important clinical implications. First, vaccines directed against components of the type III secretion system are likely to be efficacious in humans. Although such vaccines will not prevent P. aeruginosa VAP, they may significantly reduce the morbidity and mortality associated with severe disease. Second, patients infected with type-III-secreting strains would possibly benefit from particularly aggressive and prolonged antibiotic therapy. Third, diagnostic assays that determine which P. aeruginosa isolates secrete type III proteins may be useful in identifying a subset of patients likely to benefit from passive immune therapy directed against the type III system. Sawa et al. (65) leagues was published (67) . These authors found that respiratory and bloodstream infections caused by P. aeruginosa isolates capable of secreting type III proteins were associated with a sixfold increase in mortality. Thus the correlation between type III secretion and more severe disease is not limited to a single geographic locality or a specific anatomical site of infection.
In summary, the results of this study are consistent with the P. aeruginosa type III secretion system being of major importance in VAP and indicate that it may be an attractive target for novel therapeutic interventions. Indeed, our results suggest that isolates characterized by the ability to secrete detectable amounts of type III proteins are of increased virulence, and infections with such strains place patients at high risk for death or recurrence. Because antibodies against type III secretory proteins have been protective in animal models (65) , passive immunization may be useful as adjunctive therapy in VAP caused by P. aeruginosa. In addition, ventilated patients colonized with type-III-secreting isolates may warrant particularly aggressive decontamination or immunization to prevent the development of potential life-threatening episodes of pneumonia. 
